A recent analysis, led by investigators at The University of Texas MD Anderson Cancer Center, demonstrated that long-term survivors of pancreatic cancer have different microbiome signatures in their tumor microenvironments that impact the immune system compared with patients categorized as short-term survivors. Research showed that the bacteria can either stimulate or suppress immune response in patients with pancreatic cancer.
When the investigators conducted a mouse model study of fecal microbiota transplants (FMT) from patients, they found that the mice with FMT from long-term survivors had smaller tumors compared with the short-term survivors or control donors due to the composition of the tumor microbiome. Read more . . .